Phase II Open Label Trial results for prescription drug candidate, CaPre® to be presented on July 26, 2014 at 12:30 p.m.
LAVAL, Quebec, July 24, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti" or the " Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has been selected to give an oral presentation at the 19 th World Congress on Heart Disease. Pierre Lemieux, PhD, Acasti's Chief Operating Officer, will present CaPre® Phase II Open Label (COLT) trial results, previously announced in August 2013. A copy of the abstract will be available on Acasti's website upon conclusion of the conference: acastipharma.com/en/investor-relations/events. The COLT trial was a randomized open-label, dose ranging, multi-centre study designed to assess the safety and efficacy of CaPre® in mild-to-severe hypertriglyceridemic patients. CaPre® was found to be safe and effective in reducing triglyceride levels, with triglyceride lowering activity seen at all doses tested. As well, CaPre® had a positive impact on multiple lipoproteins, including high-density lipoprotein (HDL) and non-HDL, and no significant deleterious effect on low-density lipoprotein (LDL). Acasti has recently completed its other Phase II trial, the double-blind, placebo-controlled (TRIFECTA) study. Top-line results for the TRIFECTA trial are expected by the end of September 2014, with full data coming out in the following quarter. About Acasti Pharma Inc. Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids ("PUFAs"), mainly eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre®, currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. ONEMIA®, a medical food and currently Acasti's only commercialized product, is a purified omega-3 phospholipid concentrate derived from krill oil with lower levels of phospholipids, EPA and DHA content than CaPre®.